Elicio Therapeutics Anounces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Imunotherapy, ELI-02, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer athe ASCO Anual Meting Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting – CBI
Homepage /  Press Release /  Elicio Therapeutics Anounces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Imunotherapy, ELI-02, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer athe ASCO Anual Meting Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

Press Release

Elicio Therapeutics Anounces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Imunotherapy, ELI-02, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer athe ASCO Anual Meting Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting